Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash-to-Debt 1.37
MDSO's Cash-to-Debt is ranked lower than
68% of the 1921 Companies
in the Global Health Information Services industry.

( Industry Median: 10.13 vs. MDSO: 1.37 )
Ranked among companies with meaningful Cash-to-Debt only.
MDSO' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.4  Med: 21.62 Max: No Debt
Current: 1.37
Equity-to-Asset 0.50
MDSO's Equity-to-Asset is ranked lower than
66% of the 1830 Companies
in the Global Health Information Services industry.

( Industry Median: 0.60 vs. MDSO: 0.50 )
Ranked among companies with meaningful Equity-to-Asset only.
MDSO' s Equity-to-Asset Range Over the Past 10 Years
Min: -1.75  Med: 0.42 Max: 0.67
Current: 0.5
-1.75
0.67
Interest Coverage 3.19
MDSO's Interest Coverage is ranked lower than
92% of the 1467 Companies
in the Global Health Information Services industry.

( Industry Median: 173.79 vs. MDSO: 3.19 )
Ranked among companies with meaningful Interest Coverage only.
MDSO' s Interest Coverage Range Over the Past 10 Years
Min: 1.31  Med: 4.38 Max: 202.12
Current: 3.19
1.31
202.12
Piotroski F-Score: 6
Altman Z-Score: 7.67
Beneish M-Score: -2.49
WACC vs ROIC
12.22%
15.27%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating Margin % 11.47
MDSO's Operating Margin % is ranked higher than
69% of the 1862 Companies
in the Global Health Information Services industry.

( Industry Median: 4.84 vs. MDSO: 11.47 )
Ranked among companies with meaningful Operating Margin % only.
MDSO' s Operating Margin % Range Over the Past 10 Years
Min: -36.17  Med: 8.04 Max: 14
Current: 11.47
-36.17
14
Net Margin % 6.72
MDSO's Net Margin % is ranked higher than
62% of the 1863 Companies
in the Global Health Information Services industry.

( Industry Median: 3.19 vs. MDSO: 6.72 )
Ranked among companies with meaningful Net Margin % only.
MDSO' s Net Margin % Range Over the Past 10 Years
Min: -37.57  Med: 4.86 Max: 21.36
Current: 6.72
-37.57
21.36
ROE % 9.06
MDSO's ROE % is ranked higher than
57% of the 1803 Companies
in the Global Health Information Services industry.

( Industry Median: 6.16 vs. MDSO: 9.06 )
Ranked among companies with meaningful ROE % only.
MDSO' s ROE % Range Over the Past 10 Years
Min: 2.48  Med: 9.06 Max: 63.95
Current: 9.06
2.48
63.95
ROA % 4.28
MDSO's ROA % is ranked higher than
55% of the 1927 Companies
in the Global Health Information Services industry.

( Industry Median: 2.92 vs. MDSO: 4.28 )
Ranked among companies with meaningful ROA % only.
MDSO' s ROA % Range Over the Past 10 Years
Min: -106.4  Med: 4.02 Max: 22.66
Current: 4.28
-106.4
22.66
ROC (Joel Greenblatt) % 96.34
MDSO's ROC (Joel Greenblatt) % is ranked higher than
72% of the 1883 Companies
in the Global Health Information Services industry.

( Industry Median: 23.13 vs. MDSO: 96.34 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
MDSO' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -318.3  Med: 80.74 Max: 277.92
Current: 96.34
-318.3
277.92
3-Year Revenue Growth Rate 16.50
MDSO's 3-Year Revenue Growth Rate is ranked higher than
78% of the 1454 Companies
in the Global Health Information Services industry.

( Industry Median: 5.30 vs. MDSO: 16.50 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
MDSO' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -21.7  Med: 11.05 Max: 17.5
Current: 16.5
-21.7
17.5
3-Year EBITDA Growth Rate 28.40
MDSO's 3-Year EBITDA Growth Rate is ranked higher than
79% of the 1210 Companies
in the Global Health Information Services industry.

( Industry Median: 8.40 vs. MDSO: 28.40 )
Ranked among companies with meaningful 3-Year EBITDA Growth Rate only.
MDSO' s 3-Year EBITDA Growth Rate Range Over the Past 10 Years
Min: 0  Med: -0.05 Max: 28.4
Current: 28.4
0
28.4
3-Year EPS without NRI Growth Rate 18.10
MDSO's 3-Year EPS without NRI Growth Rate is ranked higher than
66% of the 1098 Companies
in the Global Health Information Services industry.

( Industry Median: 7.70 vs. MDSO: 18.10 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
MDSO' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -48.4  Med: -13.1 Max: 40.9
Current: 18.1
-48.4
40.9
GuruFocus has detected 4 Warning Signs with Medidata Solutions Inc $MDSO.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» MDSO's 30-Y Financials

Financials (Next Earnings Date: 2017-07-26 Est.)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

MDSO Guru Trades in Q2 2016

Joel Greenblatt 8,271 sh (New)
Chuck Royce 188,165 sh (unchged)
Frank Sands 4,002,133 sh (-3.35%)
Columbia Wanger 1,729,046 sh (-7.24%)
» More
Q3 2016

MDSO Guru Trades in Q3 2016

Paul Tudor Jones 6,643 sh (New)
Chuck Royce 188,165 sh (unchged)
Joel Greenblatt Sold Out
Frank Sands 3,862,933 sh (-3.48%)
Columbia Wanger 851,182 sh (-50.77%)
» More
Q4 2016

MDSO Guru Trades in Q4 2016

Jim Simons 59,894 sh (New)
Chuck Royce 188,165 sh (unchged)
Paul Tudor Jones Sold Out
Frank Sands 3,788,033 sh (-1.94%)
Columbia Wanger 795,140 sh (-6.58%)
» More
Q1 2017

MDSO Guru Trades in Q1 2017

Joel Greenblatt 26,166 sh (New)
Jim Simons 396,992 sh (+562.82%)
Chuck Royce 285,665 sh (+51.82%)
Frank Sands 3,792,633 sh (+0.12%)
Columbia Wanger 766,706 sh (-3.58%)
» More
» Details

Insider Trades

Latest Guru Trades with MDSO

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Application Software » Health Information Services    NAICS: 511210    SIC: 7372
Compare:NAS:ATHN, NAS:HQY, NAS:WBMD, NAS:INOV, NAS:PINC, NYSE:TDOC, NYSE:EVH, NAS:OMCL, NAS:QSII, NAS:HSTM, NAS:CPSI, NAS:NH, NAS:RCM, NAS:TRHC, OTCPK:COGZF, NAS:COOL, OTCPK:SNBP, OTCPK:CNAB, OTCPK:OMCM, NAS:STRM » details
Traded in other countries:2M9.Germany,
Headquarter Location:USA
Medidata Solutions Inc provides cloud-based solutions for life sciences. Its customers are pharmaceutical, biotechnology, and medical device companies, academic institutions, and contract research organizations.

Medidata provides cloud-based solutions for the clinical development programs of life sciences companies. Its customers include biopharmaceutical companies, device makers, contract research organizations, and academic institutions. The majority of the company's business comes from subscriptions to the Medidata Clinical Cloud, with the remainder of revenue coming from services. The Medidata Clinical Cloud provides solutions for study design and planning, data capture, patient activity measurement, risk-based monitoring, and payments. The services segment includes technology and support services and professional consulting services. The majority of the firm's revenue is generated within the United States.

Top Ranked Articles about Medidata Solutions Inc

Columbia Wanger's Largest Trades in 3rd Quarter The guru's most significant transactions
Columbia funds are managed by Columbia Management Investment Advisers LLC, and Columbia Acorn funds are managed by Columbia Wanger (Trades, Portfolio) Asset Management LLC, a subsidiary of Columbia Management Investment Advisers, LLC. During the third quarter the guru’s largest trades were the following: Read more...

Ratios

vs
industry
vs
history
PE Ratio 127.54
MDSO's PE Ratio is ranked lower than
90% of the 1245 Companies
in the Global Health Information Services industry.

( Industry Median: 25.80 vs. MDSO: 127.54 )
Ranked among companies with meaningful PE Ratio only.
MDSO' s PE Ratio Range Over the Past 10 Years
Min: 11.29  Med: 105.79 Max: 2129.13
Current: 127.54
11.29
2129.13
Forward PE Ratio 59.17
MDSO's Forward PE Ratio is ranked lower than
89% of the 535 Companies
in the Global Health Information Services industry.

( Industry Median: 20.20 vs. MDSO: 59.17 )
Ranked among companies with meaningful Forward PE Ratio only.
N/A
PE Ratio without NRI 127.54
MDSO's PE Ratio without NRI is ranked lower than
90% of the 1229 Companies
in the Global Health Information Services industry.

( Industry Median: 26.21 vs. MDSO: 127.54 )
Ranked among companies with meaningful PE Ratio without NRI only.
MDSO' s PE Ratio without NRI Range Over the Past 10 Years
Min: 11.06  Med: 105.6 Max: 2129.13
Current: 127.54
11.06
2129.13
Price-to-Owner-Earnings 226.48
MDSO's Price-to-Owner-Earnings is ranked lower than
96% of the 724 Companies
in the Global Health Information Services industry.

( Industry Median: 22.94 vs. MDSO: 226.48 )
Ranked among companies with meaningful Price-to-Owner-Earnings only.
MDSO' s Price-to-Owner-Earnings Range Over the Past 10 Years
Min: 28.61  Med: 180.05 Max: 10780
Current: 226.48
28.61
10780
PB Ratio 10.29
MDSO's PB Ratio is ranked lower than
82% of the 1789 Companies
in the Global Health Information Services industry.

( Industry Median: 2.97 vs. MDSO: 10.29 )
Ranked among companies with meaningful PB Ratio only.
MDSO' s PB Ratio Range Over the Past 10 Years
Min: 4.53  Med: 9.59 Max: 29.12
Current: 10.29
4.53
29.12
PS Ratio 8.59
MDSO's PS Ratio is ranked lower than
81% of the 1780 Companies
in the Global Health Information Services industry.

( Industry Median: 2.34 vs. MDSO: 8.59 )
Ranked among companies with meaningful PS Ratio only.
MDSO' s PS Ratio Range Over the Past 10 Years
Min: 1.31  Med: 6.01 Max: 12.58
Current: 8.59
1.31
12.58
Price-to-Free-Cash-Flow 57.42
MDSO's Price-to-Free-Cash-Flow is ranked lower than
78% of the 677 Companies
in the Global Health Information Services industry.

( Industry Median: 24.32 vs. MDSO: 57.42 )
Ranked among companies with meaningful Price-to-Free-Cash-Flow only.
MDSO' s Price-to-Free-Cash-Flow Range Over the Past 10 Years
Min: 13.21  Med: 45.43 Max: 268.58
Current: 57.42
13.21
268.58
Price-to-Operating-Cash-Flow 42.74
MDSO's Price-to-Operating-Cash-Flow is ranked lower than
79% of the 856 Companies
in the Global Health Information Services industry.

( Industry Median: 17.68 vs. MDSO: 42.74 )
Ranked among companies with meaningful Price-to-Operating-Cash-Flow only.
MDSO' s Price-to-Operating-Cash-Flow Range Over the Past 10 Years
Min: 10.26  Med: 35.32 Max: 135.3
Current: 42.74
10.26
135.3
EV-to-EBIT 68.57
MDSO's EV-to-EBIT is ranked lower than
86% of the 1770 Companies
in the Global Health Information Services industry.

( Industry Median: 17.68 vs. MDSO: 68.57 )
Ranked among companies with meaningful EV-to-EBIT only.
MDSO' s EV-to-EBIT Range Over the Past 10 Years
Min: 8.7  Med: 53.9 Max: 344.6
Current: 68.57
8.7
344.6
EV-to-EBITDA 53.79
MDSO's EV-to-EBITDA is ranked lower than
86% of the 1910 Companies
in the Global Health Information Services industry.

( Industry Median: 13.76 vs. MDSO: 53.79 )
Ranked among companies with meaningful EV-to-EBITDA only.
MDSO' s EV-to-EBITDA Range Over the Past 10 Years
Min: 6.8  Med: 40.8 Max: 133.6
Current: 53.79
6.8
133.6
PEG Ratio 11.92
MDSO's PEG Ratio is ranked lower than
88% of the 567 Companies
in the Global Health Information Services industry.

( Industry Median: 1.98 vs. MDSO: 11.92 )
Ranked among companies with meaningful PEG Ratio only.
MDSO' s PEG Ratio Range Over the Past 10 Years
Min: 7.97  Med: 16.07 Max: 262.93
Current: 11.92
7.97
262.93
Current Ratio 3.90
MDSO's Current Ratio is ranked higher than
79% of the 1750 Companies
in the Global Health Information Services industry.

( Industry Median: 1.94 vs. MDSO: 3.90 )
Ranked among companies with meaningful Current Ratio only.
MDSO' s Current Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.46 Max: 5.35
Current: 3.9
0.44
5.35
Quick Ratio 3.90
MDSO's Quick Ratio is ranked higher than
81% of the 1750 Companies
in the Global Health Information Services industry.

( Industry Median: 1.79 vs. MDSO: 3.90 )
Ranked among companies with meaningful Quick Ratio only.
MDSO' s Quick Ratio Range Over the Past 10 Years
Min: 0.44  Med: 2.46 Max: 5.35
Current: 3.9
0.44
5.35
Days Sales Outstanding 76.98
MDSO's Days Sales Outstanding is ranked lower than
67% of the 1492 Companies
in the Global Health Information Services industry.

( Industry Median: 68.98 vs. MDSO: 76.98 )
Ranked among companies with meaningful Days Sales Outstanding only.
MDSO' s Days Sales Outstanding Range Over the Past 10 Years
Min: 45.45  Med: 74.88 Max: 90.9
Current: 76.98
45.45
90.9
Days Payable 20.62
MDSO's Days Payable is ranked lower than
76% of the 1330 Companies
in the Global Health Information Services industry.

( Industry Median: 43.37 vs. MDSO: 20.62 )
Ranked among companies with meaningful Days Payable only.
MDSO' s Days Payable Range Over the Past 10 Years
Min: 16.07  Med: 23.22 Max: 54.1
Current: 20.62
16.07
54.1

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -2.50
MDSO's 3-Year Average Share Buyback Ratio is ranked higher than
50% of the 1148 Companies
in the Global Health Information Services industry.

( Industry Median: -2.60 vs. MDSO: -2.50 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
MDSO' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -55.7  Med: -4 Max: -2.5
Current: -2.5
-55.7
-2.5

Valuation & Return

vs
industry
vs
history
Price-to-Net-Current-Asset-Value 53.85
MDSO's Price-to-Net-Current-Asset-Value is ranked lower than
90% of the 1066 Companies
in the Global Health Information Services industry.

( Industry Median: 7.31 vs. MDSO: 53.85 )
Ranked among companies with meaningful Price-to-Net-Current-Asset-Value only.
MDSO' s Price-to-Net-Current-Asset-Value Range Over the Past 10 Years
Min: 8.65  Med: 25.01 Max: 4775
Current: 53.85
8.65
4775
Price-to-Tangible-Book 11.79
MDSO's Price-to-Tangible-Book is ranked lower than
71% of the 1488 Companies
in the Global Health Information Services industry.

( Industry Median: 4.38 vs. MDSO: 11.79 )
Ranked among companies with meaningful Price-to-Tangible-Book only.
MDSO' s Price-to-Tangible-Book Range Over the Past 10 Years
Min: 6.33  Med: 10.61 Max: 154.69
Current: 11.79
6.33
154.69
Price-to-Intrinsic-Value-Projected-FCF 4.28
MDSO's Price-to-Intrinsic-Value-Projected-FCF is ranked lower than
71% of the 771 Companies
in the Global Health Information Services industry.

( Industry Median: 1.97 vs. MDSO: 4.28 )
Ranked among companies with meaningful Price-to-Intrinsic-Value-Projected-FCF only.
MDSO' s Price-to-Intrinsic-Value-Projected-FCF Range Over the Past 10 Years
Min: 2.98  Med: 5.23 Max: 10.1
Current: 4.28
2.98
10.1
Price-to-Median-PS-Value 1.44
MDSO's Price-to-Median-PS-Value is ranked lower than
56% of the 1498 Companies
in the Global Health Information Services industry.

( Industry Median: 1.15 vs. MDSO: 1.44 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
MDSO' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.22  Med: 0.97 Max: 1.97
Current: 1.44
0.22
1.97
Price-to-Peter-Lynch-Fair-Value 10.36
MDSO's Price-to-Peter-Lynch-Fair-Value is ranked lower than
96% of the 339 Companies
in the Global Health Information Services industry.

( Industry Median: 1.60 vs. MDSO: 10.36 )
Ranked among companies with meaningful Price-to-Peter-Lynch-Fair-Value only.
MDSO' s Price-to-Peter-Lynch-Fair-Value Range Over the Past 10 Years
Min: 8.22  Med: 10.33 Max: 18.42
Current: 10.36
8.22
18.42
Price-to-Graham-Number 8.18
MDSO's Price-to-Graham-Number is ranked lower than
85% of the 882 Companies
in the Global Health Information Services industry.

( Industry Median: 2.52 vs. MDSO: 8.18 )
Ranked among companies with meaningful Price-to-Graham-Number only.
MDSO' s Price-to-Graham-Number Range Over the Past 10 Years
Min: 1.88  Med: 7.38 Max: 29.72
Current: 8.18
1.88
29.72
Earnings Yield (Greenblatt) % 1.46
MDSO's Earnings Yield (Greenblatt) % is ranked lower than
59% of the 2521 Companies
in the Global Health Information Services industry.

( Industry Median: 3.23 vs. MDSO: 1.46 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
MDSO' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: 0.3  Med: 1.9 Max: 11.5
Current: 1.46
0.3
11.5
Forward Rate of Return (Yacktman) % 13.47
MDSO's Forward Rate of Return (Yacktman) % is ranked higher than
50% of the 773 Companies
in the Global Health Information Services industry.

( Industry Median: 10.33 vs. MDSO: 13.47 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
MDSO' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -2.7  Med: 1 Max: 21.2
Current: 13.47
-2.7
21.2

More Statistics

Revenue (TTM) (Mil) $486.0
EPS (TTM) $ 0.57
Beta1.73
Short Percentage of Float12.03%
52-Week Range $41.65 - 73.75
Shares Outstanding (Mil)58.36

Analyst Estimate

Dec17 Dec18
Revenue (Mil $) 553 640
EPS ($) 1.23 1.50
EPS without NRI ($) 1.23 1.50
EPS Growth Rate
(Future 3Y To 5Y Estimate)
N/A
Dividends per Share ($)
» More Articles for MDSO

Headlines

Articles On GuruFocus.com
Trump's New Health Care Frontier Mar 14 2017 
These Stocks Are More Than You Think Nov 21 2016 
Columbia Wanger's Largest Trades in 3rd Quarter Nov 11 2016 
There’s More In The Clouds At Medidata Than Just The Valuation Jul 21 2015 
Frank Sands Adds to His Position in Medidata Solutions, Inc. Jul 14 2015 
Medidata: SaaS Business Model Leveraging Growth Of The Company Oct 23 2014 
Frank Sands Adds 5 New Stocks Aug 14 2014 
Medidata Solutions: Benefit from Growing Cloud Applications with This Stock May 27 2014 
Medidata Solutions : A SAAS Provider For Your Portfolio Mar 23 2014 
Medidata Solutions Inc. (MDSO) Chairman & CEO Tarek Sherif sells 8,667 Shares Mar 08 2011 

More From Other Websites
Medidata to Present at Bank of America Merrill Lynch 2017 Global Technology Conference May 25 2017
Post Earnings Coverage as Premier's Q3 Non-GAAP EPS Rose 18% Y-o-Y to Beat Market Forecasts May 24 2017
Medidata to Present First-of-its-kind Scientific Innovation at 2017 ASCO Annual Meeting May 17 2017
Medytox to Further Expand Global Presence by Increasing Its Adoption of the Medidata Clinical... May 15 2017
UPDATED PRESENTATION TIME FOR MAY 22: Medidata to Present at Upcoming Investor Conference May 15 2017
Medidata’s Julie Iskow Named a “Luminary” by the Healthcare Businesswomen’s Association May 11 2017
Computer Programs and Systems (CPSI) Jumps: Stock Rises 15% May 08 2017
Medidata Introduces Regulated Content and Document Management Capabilities to Its Industry-Leading... May 08 2017
Medidata to Present at Upcoming Investor Conferences May 03 2017
Edited Transcript of MDSO earnings conference call or presentation 26-Apr-17 12:00pm GMT Apr 28 2017
Medidata beats Street 1Q forecasts Apr 26 2017
Medidata Reports Record First Quarter 2017 Results Apr 26 2017
UCB Selects Medidata Clinical Cloud® to Support Patient-Centric Drug Development Apr 26 2017
WuXi Clinical Development Services Expands Use of Medidata’s Cloud Technology Platform Apr 24 2017
Medidata to Acquire Mytrus to Take Next Step in Transforming the Clinical Trial Patient Experience Apr 17 2017
Medidata Schedules First Quarter Earnings Conference Call for April 26, 2017 Apr 12 2017
Medidata & TESARO Win CARE 'Clinical Partnership' Award Apr 07 2017
Medidata Wins Informa CARE Award for “Clinical Trial Partnership of the Year” Apr 06 2017
Karyopharm and Medidata Expand Clinical Trial Partnership Apr 04 2017
Medidata Clinical Cloud Selected for AML Master Trial by LLS Mar 24 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)